• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

南非一家儿童医院产碳青霉烯酶肠杆菌科细菌患者使用头孢他啶-阿维巴坦治疗的情况

Ceftazidime-Avibactam Treatment for Carbapenemase-Producing Enterobacterales in a South African Children's Hospital.

机构信息

Medical Microbiology, National Health Laboratory Service, Red Cross War Memorial Children's Hospital, Cape Town, South Africa.

Medical School, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

出版信息

J Pediatric Infect Dis Soc. 2024 Nov 4;13(10):541-546. doi: 10.1093/jpids/piae087.

DOI:10.1093/jpids/piae087
PMID:39212974
Abstract

This study describes ceftazidime-avibactam use in 17 young children from a resource-constrained country, where intra-abdominal infection was common. All-cause mortality was 53%. Earlier initiation, dose optimization, recording infusion times, and reviewing the need for additional antibiotics were identified as easy-to-implement-antimicrobial-stewardship interventions.

摘要

本研究描述了在资源有限的国家中 17 名幼儿使用头孢他啶-阿维巴坦的情况,这些儿童的常见感染部位为腹腔。全因死亡率为 53%。研究认为,早期启动、优化剂量、记录输注时间以及评估是否需要额外使用抗生素是易于实施的抗菌药物管理干预措施。

相似文献

1
Ceftazidime-Avibactam Treatment for Carbapenemase-Producing Enterobacterales in a South African Children's Hospital.南非一家儿童医院产碳青霉烯酶肠杆菌科细菌患者使用头孢他啶-阿维巴坦治疗的情况
J Pediatric Infect Dis Soc. 2024 Nov 4;13(10):541-546. doi: 10.1093/jpids/piae087.
2
Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam.产 OXA-48 碳青霉烯酶肠杆菌科细菌感染患者应用头孢他啶-阿维巴坦治疗的临床特征和预后
Int J Antimicrob Agents. 2019 Apr;53(4):520-524. doi: 10.1016/j.ijantimicag.2018.11.015. Epub 2018 Nov 22.
3
Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.治疗除肺炎克雷伯菌以外的耐药菌的头孢他啶/阿维巴坦的临床经验。
Int J Antimicrob Agents. 2018 Apr;51(4):629-635. doi: 10.1016/j.ijantimicag.2018.01.016. Epub 2018 Feb 2.
4
Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae.头孢他啶/阿维巴坦作为治疗产 OXA-48 碳青霉烯酶肠杆菌科感染的补救治疗的疗效。
J Antimicrob Chemother. 2018 Nov 1;73(11):3170-3175. doi: 10.1093/jac/dky295.
5
Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.头孢他啶-阿维巴坦治疗耐碳青霉烯类肠杆菌科细菌感染患者结局的多中心研究
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00449-17. Print 2017 Jul.
6
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.多黏菌素与头孢他啶-阿维巴坦治疗碳青霉烯类耐药肠杆菌科细菌感染。
Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783.
7
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
8
Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.头孢他啶/阿维巴坦对多重耐药肠杆菌科和铜绿假单胞菌的临床活性:来自头孢他啶/阿维巴坦 III 期临床试验计划的汇总数据。
J Antimicrob Chemother. 2018 Sep 1;73(9):2519-2523. doi: 10.1093/jac/dky204.
9
Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Infections.美罗培南-维巴坦与头孢他啶-阿维巴坦治疗碳青霉烯类耐药感染。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02313-19.
10
Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015.2012 年至 2015 年期间,作为国际最佳耐药监测网络(INFORM)全球监测项目的一部分,分离出携带 OXA-48 酶的肠杆菌科细菌,对头孢他啶-阿维巴坦和氨曲南-阿维巴坦的活性进行评估。
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.00592-18. Print 2018 Dec.

引用本文的文献

1
Carbapenem-resistant Enterobacterales colonisation in a tertiary PICU, Cape Town, South Africa.南非开普敦一家三级儿科重症监护病房中耐碳青霉烯类肠杆菌科细菌的定植情况
S Afr J Infect Dis. 2025 Jun 11;40(1):720. doi: 10.4102/sajid.v40i1.720. eCollection 2025.